Potassium
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Potassium: From Electrolyte Replacement to Hypertensive Disorder
One-Sentence Summary
Potassium is an essential electrolyte principally used for the prevention and treatment of hypokalemia (potassium deficiency); detailed original-indication and mechanism-of-action records are not yet available in this evidence pack. The TxGNN model predicts it may also be effective for Hypertensive Disorder, with 50 clinical trials and 20 publications screened, though only a subset directly involves potassium as the intervention. Overall evidence strength reaches L1, but a blocking data gap (missing SAHPRA-approved Professional Information) must be closed before safety evaluation can proceed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — potassium is generically used for electrolyte replacement / hypokalemia correction; no SAHPRA-approved product record on file |
| Predicted New Indication | Hypertensive Disorder |
| TxGNN Prediction Score | 99.16% |
| Evidence Level | L1 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data for this drug entry is not available. Based on known pharmacology, potassium is the principal intracellular cation and is central to cell membrane potential, neuromuscular signalling, and renal electrolyte handling; its use in preventing and correcting hypokalemia is long established, and mechanistically it may extend to blood pressure regulation.
The repurposing rationale for this candidate centres on potassium’s action on renal sodium handling: potassium inhibits the renal NaCl cotransporter (NCC), promotes natriuresis, reduces vascular smooth-muscle tone, and modulates the renin-angiotensin-aldosterone system (RAAS) — mechanisms that are already recognised antihypertensive pathways.
High-potassium diets and potassium-based salt substitutes have been incorporated into multiple national hypertension-prevention guidelines, which lends external plausibility to the TxGNN prediction. The principal safety concern is hyperkalemia, particularly in patients with chronic kidney disease (CKD) or those on RAAS-active antihypertensives (ACEi/ARB/MRA), where potassium handling is already impaired.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02759367 | NA | Completed | 20 | Evaluates whether increasing dietary potassium intake causes hyperkalemia in hypertensive patients on RAAS-antagonist therapy |
| NCT00160368 | Phase 3 | Unknown | 45 | Effect of potassium bicarbonate and potassium chloride on blood pressure and markers of target-organ damage in hypertensives |
| NCT00000521 | Phase 4 | Completed | 285 | Sodium-Potassium Blood Pressure Trial in Children — effect of nutritional intervention on BP rise in late childhood/adolescence |
| NCT01650012 | NA | Completed | 158 | Eplerenone (aldosterone antagonist) pilot trial in dialysis patients — mechanistically linked to potassium/aldosterone homeostasis, not a direct potassium intervention |
| NCT03917758 | NA | Unknown | 30 | Assessment of RAAS and antidiuretic function with SGLT2 inhibitors in type 2 diabetes — mechanism-related, indirect potassium relevance |
| NCT02697708 | Phase 1/2 | Unknown | 40 | Compares potato, French-fry, and supplement sources of potassium for uptake/retention and effect on BP and acid-base balance |
| NCT04894344 | NA | Completed | 196 | Education intervention to reduce sodium intake in university students, evaluated with 24-hour urinary sodium/potassium excretion |
| NCT05991050 | NA | Unknown | 30 | Whole-body vibration combined with a high-potassium DASH-style diet on blood pressure in obese postmenopausal women |
Relevance grading in the source evidence pack marks most of the above trials as “pending” (not yet human-reviewed); NCT01650012 and NCT03917758 were graded “B” (mechanistically related but not a direct potassium intervention).
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34459569 | 2021 | RCT | New England Journal of Medicine | Salt substitute with reduced sodium and added potassium lowers cardiovascular events and death |
| 32500831 | 2020 | Review (Meta-analysis of RCTs) | Journal of the American Heart Association | Dose-response meta-analysis confirms potassium supplementation lowers blood pressure |
| 23558164 | 2013 | Review (Systematic review) | BMJ | Increased potassium intake reduces blood pressure and stroke risk; effect on other CV outcomes less certain |
| 39472546 | 2025 | Review | Hypertension Research | Role of dietary potassium and salt substitution in prevention and management of hypertension |
| 37772757 | 2024 | Review | American Journal of Hypertension | State-of-the-art review of potassium’s role in blood pressure control |
| 30190007 | 2018 | Review | Journal of the American College of Cardiology | Inadequate dietary potassium identified as a modifiable risk factor for hypertension |
| 27455317 | 2016 | Review | Nutrients | Potassium intake, bioavailability, hypertension, and glucose control |
| 10979053 | 2000 | Review (Guideline) | Archives of Internal Medicine | National Council on Potassium in Clinical Practice — contemporary guidelines for potassium replacement |
| 37676724 | 2023 | Mechanistic study | Journal of Clinical Investigation | Dietary potassium dephosphorylates the renal NaCl cotransporter (NCC), reducing blood pressure |
| 26634368 | 2016 | Review | Journal of Physiology and Biochemistry | Role of dietary potassium in hypertension and diabetes |
South Africa Market Information
No SAHPRA-registered products were found for this candidate (0 registrations, market status: Not Marketed). No dosage-form or Essential Medicines List (EML) data is available to report.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
(No drug interaction data was found in this evidence pack; hyperkalemia risk in CKD and RAAS-active-drug co-therapy is noted above under mechanistic rationale, but is not sourced from a formal safety dataset here.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic link between potassium and blood pressure regulation is well supported by high-quality literature (including an NEJM RCT and multiple systematic reviews/meta-analyses), reaching Evidence Level L1. However, a Blocking data gap — absence of a SAHPRA-approved Professional Information (PI) covering warnings and contraindications — prevents completion of the initial safety assessment (S1), so this candidate cannot advance past guarded evaluation until that gap is closed.
To proceed, the following is needed:
- SAHPRA-approved Professional Information / label (warnings, precautions, contraindications) — currently missing (Blocking)
- Confirmed mechanism of action (MOA) data from DrugBank or equivalent source — currently missing (High priority)
- A direct interventional trial or dedicated systematic review evaluating potassium supplementation (as opposed to dietary/salt-substitute potassium) specifically for hypertension
- Hyperkalemia risk assessment protocol for patients with CKD or on RAAS-active antihypertensives before any clinical use is considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.